Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | RARA | P10276 | 6/20 | 0.56 |
| ▸ | RARB | P10826 | 6/20 | 0.56 |
| ▸ | RARG | P13631 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445897 | 0.85 | NR1H4 (0.56) | NR1H4ACHERARARARBRARG | |
| SCHEMBL9060639 | 0.85 | S1PR1 (0.60) | NR1H4ACHERARARARBRARG | |
| SCHEMBL5122825 | 0.85 | NR1H4 (0.60) | NR1H4ACHERARARARBRARG | |
| SCHEMBL31227031 | 0.85 | ACHE (0.57) | NR1H4ACHERARARARBRARG | |
| SCHEMBL22628885 | 0.85 | ACHE (0.62) | NR1H4ACHELMNATHRBTP53 | |
| SCHEMBL17612678 | 0.83 | NPC1 (0.71) | NR1H4RARARARBRARGTP53 | |
| SCHEMBL19131316 | 0.83 | NPC1 (0.71) | NR1H4RARARARBRARGTP53 | |
| SCHEMBL13415305 | 0.83 | ACHE (0.80) | NR1H4ACHELMNATHRBTP53 | |
| SCHEMBL22628886 | 0.82 | ACHE (0.54) | NR1H4ACHERARARARBRARG | |
| SCHEMBL13061186 | 0.82 | ACHE (0.54) | NR1H4ACHELMNATHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2731932-B1 | AMINOMETHYL QUINOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-12-30 | — | — | EP | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| WO-2009019163-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| WO-2008000729-A1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1675838-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005040144-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | NR1H4 2683/4885ACHE 4740/4885RARA 1654/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | NR1H4 3086/4885ACHE 4620/4885RARA 1235/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | NR1H4 3086/4885ACHE 4620/4885RARA 1235/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | NR1H4 3086/4885ACHE 4620/4885RARA 1235/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | NR1H4 3374/4885ACHE 4596/4885RARA 1399/4885 |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | NR1H4 606/4885ACHE 23/4885RARA 687/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | NR1H4 668/4885ACHE 706/4885RARA 2187/4885 |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GPR68, GPR88, GPR3 | NR1H4 84/4885ACHE 4067/4885RARA 3497/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | NR1H4 2006/4885ACHE 2683/4885RARA 3060/4885 |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | HRH3, HRH4, HRH1 | NR1H4 135/4885ACHE 406/4885RARA 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.